{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:52Z","timestamp":1787020732423,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor outcomes, especially in older AML patients. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered a promising anticancer drug because it selectively induces the extrinsic apoptosis of tumor cells without affecting normal cells. However, clinical trials have shown that the responses of patients to TRAIL are significantly heterogeneous. It is necessary to explore predictable biomarkers for the preselection of AML patients with better responsiveness to TRAIL. Here, we investigated the critical role of tumor protein p53 inducible nuclear protein 2 (TP53INP2) in the AML cell response to TRAIL treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>First, the relationship between TP53INP2 and the sensitivity of AML cells to TRAIL was determined by bioinformatics analysis of Cancer Cell Line Encyclopedia datasets, Cell Counting Kit-8 assays, flow cytometry (FCM) and cell line-derived xenograft (CDX) mouse models. Second, the mechanisms by which TP53INP2 participates in the response to TRAIL were analyzed by Western blot, ubiquitination, coimmunoprecipitation and immunofluorescence assays. Finally, the effect of TRAIL alone or in combination with the BCL-2 inhibitor venetoclax (VEN) on cell survival was explored using colony formation and FCM assays, and the effect on leukemogenesis was further investigated in a patient-derived xenograft (PDX) mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AML cells with high TP53INP2 expression were more sensitive to TRAIL in vitro and in vivo. Gain- and loss-of-function studies demonstrated that TP53INP2 significantly enhanced TRAIL-induced apoptosis, especially in AML cells with nucleophosmin 1 (NPM1) mutations. Mechanistically, cytoplasmic TP53INP2 maintained by mutant NPM1 functions as a scaffold bridging the ubiquitin ligase TRAF6 to caspase-8 (CASP 8), thereby promoting the ubiquitination and activation of the CASP 8 pathway. More importantly, simultaneously stimulating extrinsic and intrinsic apoptosis signaling pathways with TRAIL and VEN showed strong synergistic antileukemic activity in AML cells with high levels of TP53INP2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings revealed that TP53INP2 is a predictor of responsiveness to TRAIL treatment and supported a potentially individualized therapeutic strategy for TP53INP2-positive AML patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-03100-0","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T03:02:39Z","timestamp":1719025359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia"],"prefix":"10.1186","volume":"43","author":[{"given":"Jun","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zesong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"issue":"10393","key":"3100_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073\u201386.","journal-title":"Lancet"},{"issue":"2","key":"3100_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"9","key":"3100_CR3","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/ajh.26989","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B. NPM1-mutated acute myeloid leukemia: new pathogenetic and therapeutic insights and open questions. Am J Hematol. 2023;98(9):1452\u201364.","journal-title":"Am J Hematol"},{"issue":"2","key":"3100_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308\u201320.","journal-title":"Haematologica"},{"issue":"3","key":"3100_CR5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326.","journal-title":"Am J Hematol"},{"issue":"1","key":"3100_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3100_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506\u201325.","journal-title":"Cancer Discov"},{"issue":"2","key":"3100_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","volume":"30","author":"A Montinaro","year":"2023","unstructured":"Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ. 2023;30(2):237\u201349.","journal-title":"Cell Death Differ"},{"key":"3100_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116041","volume":"221","author":"A Maji","year":"2024","unstructured":"Maji A, Paul A, Sarkar A, Nahar S, Bhowmik R, Samanta A, et al. Significance of TRAIL\/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: implications for cancer-targeted therapeutics. Biochem Pharmacol. 2024;221: 116041.","journal-title":"Biochem Pharmacol"},{"key":"3100_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.628332","volume":"8","author":"M Snajdauf","year":"2021","unstructured":"Snajdauf M, Havlova K, Vachtenheim J Jr, Ozaniak A, Lischke R, Bartunkova J, et al. The TRAIL in the treatment of human cancer: an update on clinical trials. Front Mol Biosci. 2021;8: 628332.","journal-title":"Front Mol Biosci"},{"key":"3100_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104716","volume":"155","author":"H Dianat-Moghadam","year":"2020","unstructured":"Dianat-Moghadam H, Heidarifard M, Mahari A, Shahgolzari M, Keshavarz M, Nouri M, et al. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res. 2020;155: 104716.","journal-title":"Pharmacol Res"},{"issue":"12","key":"3100_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.trecan.2020.06.006","volume":"6","author":"D Deng","year":"2020","unstructured":"Deng D, Shah K. TRAIL of hope meeting resistance in cancer. Trends Cancer. 2020;6(12):989\u20131001.","journal-title":"Trends Cancer"},{"issue":"326","key":"3100_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jconrel.2020.07.013","volume":"10","author":"B Thapa","year":"2020","unstructured":"Thapa B, Kc R, Uluda\u011f H. TRAIL therapy and prospective developments for cancer treatment. J Control Release. 2020;10(326):335\u201349.","journal-title":"J Control Release"},{"key":"3100_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.critrevonc.2019.08.008","volume":"143","author":"SHM Wong","year":"2019","unstructured":"Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, Abdullah S, et al. The TRAIL to cancer therapy: hindrances and potential solutions. Crit Rev Oncol Hematol. 2019;143:81\u201394.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3100_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semcancer.2019.01.007","volume":"58","author":"S Fayyaz","year":"2019","unstructured":"Fayyaz S, Javed Z, Attar R, Farooqi AA, Yaylim I, Ahmad A. MicroRNA regulation of TRAIL mediated signaling in different cancers: control of micro steering wheels during the journey from bench-top to the bedside. Semin Cancer Biol. 2019;58:56\u201364.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"3100_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41419-018-1160-2","volume":"9","author":"FA Lincoln","year":"2018","unstructured":"Lincoln FA, Imig D, Boccellato C, Juric V, Noonan J, Kontermann RE, et al. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism. Cell Death Dis. 2018;9(11):1112.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3100_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood.2021014670","volume":"141","author":"A Ediriwickrema","year":"2023","unstructured":"Ediriwickrema A, Gentles AJ, Majeti R. Single-cell genomics in AML: extending the frontiers of AML research. Blood. 2023;141(4):345\u201355.","journal-title":"Blood"},{"issue":"9","key":"3100_CR18","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/s41418-020-0539-7","volume":"27","author":"JZ Roberts","year":"2020","unstructured":"Roberts JZ, Holohan C, Sessler T, Fox J, Crawford N, Riley JS, et al. The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death Differ. 2020;27(9):2726\u201341.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3100_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13046-020-01794-6","volume":"40","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Satta A, Garrone G, Cavalleri A, Napoli A, Raspagliesi F, et al. Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. J Exp Clin Cancer Res. 2021;40(1):5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"3100_CR20","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899300","volume":"38","author":"S Ivanova","year":"2019","unstructured":"Ivanova S, Polajnar M, Narbona-Perez AJ, Hernandez-Alvarez MI, Frager P, Slobodnyuk K, et al. Regulation of death receptor signaling by the autophagy protein TP53INP2. EMBO J. 2019;38(10): e99300.","journal-title":"EMBO J"},{"issue":"2","key":"3100_CR21","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/ijms24021624","volume":"24","author":"J Huang","year":"2023","unstructured":"Huang J, Sun M, Tao Y, Ren J, Peng M, Jing Y, et al. Cytoplasmic expression of TP53INP2 modulated by demethylase FTO and mutant NPM1 promotes autophagy in leukemia cells. Int J Mol Sci. 2023;24(2):1624.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"3100_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136(15):1707\u201321.","journal-title":"Blood"},{"issue":"7784","key":"3100_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","volume":"575","author":"M Fritsch","year":"2019","unstructured":"Fritsch M, G\u00fcnther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683\u20137.","journal-title":"Nature"},{"issue":"2","key":"3100_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41418-021-00922-9","volume":"29","author":"JZ Roberts","year":"2022","unstructured":"Roberts JZ, Crawford N, Longley DB. The role of ubiquitination in apoptosis and necroptosis. Cell Death Differ. 2022;29(2):272\u201384.","journal-title":"Cell Death Differ"},{"issue":"9","key":"3100_CR25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/cdd.2017.89","volume":"24","author":"MCC Lim","year":"2017","unstructured":"Lim MCC, Maubach G, Sokolova O, Feige MH, Diezko R, Buchbinder J, et al. Pathogen-induced ubiquitin-editing enzyme A20 bifunctionally shuts off NF-\u03baB and caspase-8-dependent apoptotic cell death. Cell Death Differ. 2017;24(9):1621\u201331.","journal-title":"Cell Death Differ"},{"issue":"7","key":"3100_CR26","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.3390\/ijms24076725","volume":"24","author":"E Kelland","year":"2023","unstructured":"Kelland E, Patil MS, Patel S, Cartland SP, Kavurma MM. The prognostic, diagnostic, and therapeutic potential of TRAIL signalling in cardiovascular diseases. Int J Mol Sci. 2023;24(7):6725.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"3100_CR27","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.3390\/cells11233717","volume":"11","author":"M Kundu","year":"2022","unstructured":"Kundu M, Greer YE, Dine JL, Lipkowitz S. Targeting TRAIL death receptors in triple-negative breast cancers: challenges and strategies for cancer therapy. Cells. 2022;11(23):3717.","journal-title":"Cells"},{"issue":"1","key":"3100_CR28","first-page":"vdad047","volume":"5","author":"M Thang","year":"2023","unstructured":"Thang M, Mellows C, Mercer-Smith A, Nguyen P, Hingtgen S. Current approaches in enhancing TRAIL therapies in glioblastoma. Neurooncol Adv. 2023;5(1):vdad047.","journal-title":"Neurooncol Adv"},{"issue":"3","key":"3100_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4161\/auto.5.3.7698","volume":"5","author":"J Nowak","year":"2009","unstructured":"Nowak J, Iovanna JL. TP53INP2 is the new guest at the table of self-eating. Autophagy. 2009;5(3):383\u20134.","journal-title":"Autophagy"},{"key":"3100_CR30","doi-asserted-by":"publisher","unstructured":"Sebasti\u00e1n D, Beltr\u00e0 M, Irazoki A, Sala D, Aparicio P, Aris C, et al. TP53INP2-dependent activation of muscle autophagy ameliorates sarcopenia and promotes healthy aging. Autophagy. 2024:1\u201310. https:\/\/doi.org\/10.1080\/15548627.2024.2333717.","DOI":"10.1080\/15548627.2024.2333717"},{"issue":"1","key":"3100_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2008.09.004","volume":"274","author":"DH Cho","year":"2009","unstructured":"Cho DH, Jo YK, Hwang JJ, Lee YM, Roh SA, Kim JC. Caspase-mediated cleavage of ATG6\/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett. 2009;274(1):95\u2013100.","journal-title":"Cancer Lett"},{"key":"3100_CR32","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.biopha.2018.08.065","volume":"107","author":"R Saraei","year":"2018","unstructured":"Saraei R, Soleimani M, Movassaghpour Akbari AA, Farshdousti Hagh M, Hassanzadeh A, Solali S. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Biomed Pharmacother. 2018;107:1010\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3100_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188357","volume":"1873","author":"R Mandal","year":"2020","unstructured":"Mandal R, Barr\u00f3n JC, Kostova I, Becker S, Strebhardt K. Caspase-8: the double-edged sword. Biochim Biophys Acta Rev Cancer. 2020;1873(2): 188357.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"3100_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/15548627.2020.1713646","volume":"16","author":"Y Xu","year":"2020","unstructured":"Xu Y, Wan W. The bifunctional role of TP53INP2 in transcription and autophagy. Autophagy. 2020;16(7):1341\u20133.","journal-title":"Autophagy"},{"issue":"7","key":"3100_CR35","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1080\/15548627.2016.1175693","volume":"12","author":"Y Xu","year":"2016","unstructured":"Xu Y, Wan W, Shou X, Huang R, You Z, Shou Y, et al. TP53INP2\/DOR, a mediator of cell autophagy, promotes rDNA transcription via facilitating the assembly of the POLR1\/RNA polymerase I preinitiation complex at rDNA promoters. Autophagy. 2016;12(7):1118\u201328.","journal-title":"Autophagy"},{"issue":"15","key":"3100_CR36","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/cells11152385","volume":"11","author":"Y Cui","year":"2022","unstructured":"Cui Y, Yang H, Shi S, Ping X, Zheng S, Tang X, et al. TP53INP2 Contributes to TGF-\u03b22-induced autophagy during the epithelial-mesenchymal transition in posterior capsular opacification development. Cells. 2022;11(15):2385.","journal-title":"Cells"},{"issue":"2","key":"3100_CR37","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201903183RRR","volume":"35","author":"Y Tang","year":"2021","unstructured":"Tang Y, Tao Y, Wang L, Yang L, Jing Y, Jiang X, et al. NPM1 mutant maintains ULK1 protein stability via TRAF6-dependent ubiquitination to promote autophagic cell survival in leukemia. FASEB J. 2021;35(2): e21192.","journal-title":"FASEB J"},{"issue":"8","key":"3100_CR38","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/15548627.2019.1580510","volume":"15","author":"Z You","year":"2019","unstructured":"You Z, Xu Y, Wan W, Zhou L, Li J, Zhou T, et al. TP53INP2 contributes to autophagosome formation by promoting LC3-ATG7 interaction. Autophagy. 2019;15(8):1309\u201321.","journal-title":"Autophagy"},{"issue":"11","key":"3100_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.464","volume":"4","author":"Y Li","year":"2013","unstructured":"Li Y, Kong Y, Zhou Z, Chen H, Wang Z, Hsieh YC, et al. The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8. Cell Death Dis. 2013;4(11): e935.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3100_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.molcel.2012.09.031","volume":"48","author":"F Gonzalvez","year":"2012","unstructured":"Gonzalvez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, et al. TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell. 2012;48(6):888\u201399.","journal-title":"Mol Cell"},{"issue":"7","key":"3100_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3100_CR42","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41418-019-0465-8","volume":"27","author":"J Dittmann","year":"2020","unstructured":"Dittmann J, Haydn T, Metzger P, Ward GA, Boerries M, Vogler M, et al. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. Cell Death Differ. 2020;27(6):1878\u201395.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3100_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22(1):45\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"3100_CR44","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. First-line Venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388(19):1739\u201354.","journal-title":"N Engl J Med"},{"issue":"22","key":"3100_CR45","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401\u20139.","journal-title":"Blood"},{"issue":"15","key":"3100_CR46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3100_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"1","key":"3100_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-023-02750-w","volume":"42","author":"T Gaur","year":"2023","unstructured":"Gaur T, Poddutoori R, Khare L, Bagal B, Rashmi S, Patkar N, et al. el covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax. J Exp Clin Cancer Res. 2023;42(1):186.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3100_CR49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13046-022-02542-8","volume":"41","author":"K Fooks","year":"2022","unstructured":"Fooks K, Galicia-Vazquez G, Gife V, Schcolnik-Cabrera A, Nouhi Z, Poon WWL, et al. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. J Exp Clin Cancer Res. 2022;41(1):340.","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"3100_CR50","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood.2022017333","volume":"141","author":"SK Tahir","year":"2023","unstructured":"Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, et al. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023;141(17):2114\u201326.","journal-title":"Blood"},{"issue":"10","key":"3100_CR51","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"issue":"20","key":"3100_CR52","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140(20):2113\u201326.","journal-title":"Blood"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03100-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T03:07:00Z","timestamp":1719025620000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03100-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3100"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03100-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was given by the Medical Ethics Committee of Chongqing Medical University. All the mice were raised by the Laboratory Animal Center of Chongqing Medical University and approved by the Animal Ethics Committee of Chongqing Medical University. All animal work was conducted according to the approved protocols and the institutional animal welfare guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are aware of and agree to the content of the paper and their being listed as\u00a0a co-author of the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}